Value in Health · 2019 · 46 citations · 26 references
MedicineOncologyPharmacoeconomicsChemotherapyCost-effectiveness AnalysisPharmacoeconomic ModelingAdjuvant ChemotherapyAdjuvant PharmacotherapyAdjuvant TherapyCost-effectiveness ComparisonCost-effectiveness ModelingHer2-positive Breast CancerAdjuvant Her2-directed TherapyBreast Cancer ChemotherapyCancer Cost BurdenCost-effectivenessCost-effectiveness Analysis PerspectiveHer2-positive Breast Cancer TherapyHuman Epidermal Growth Factor Receptor 2-Targeted TherapyPertuzumab Therapy
26
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2017 · 15K citations · Full text
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond, Edith A. Perez, John Bryant et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis J. Slamon, W. Eiermann, Nicholas J. Robert et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text
Medicine, Oncology, Pharmacology +17
Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.4K citations
Medicine, Oncology, Pharmacology +16